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Welcome to a new series of articles on stem cell genomics 
to be published in this and upcoming issues of Genome 
Medicine. These contributions sample just a few of the 
many exciting developments in the field of stem cells and 
genomic research and project ahead to future advances 
that will make a clear imprint on medicine.
Simply put, stem cells are defined by two properties: 
self-renewal, the generation of more identical cells, and 
developmental potency, the capacity to give rise to more 
differentiated cells. Stem cells come in different ‘flavors’. 
Blood-forming (hematopoietic) stem cells (HSCs), which 
sustain  blood  formation  through  our  entire  lives,  are 
restricted  in  their  developmental  potential  to  generate 
only blood cell lineages. On the other hand, embryonic 
stem (ES) cells can produce the entire repertoire of cells 
of the body, a property called pluripotency. Although the 
varieties  of  stem  cells  are  diverse,  it  is  increasingly 
evident  that  fundamental  principles  and  mechanisms 
underlie self-renewal and differentiation, such that dis-
parate  research  communities  are  brought  together  by 
common biological themes.
From all the recent excitement in the media about new 
developments in stem cells, one might think that stem 
cells  were  hitherto  unknown.  Nothing  can  be  further 
from  the  truth.  Indeed,  bone  marrow  transplantation 
(BMT), a life-saving procedure for which the Nobel Prize 
was  awarded  to  E  Donnall  Thomas  in  1990,  has  been 
used for more than three decades to treat aplastic anemia 
and  leukemia  [1].  Remarkably,  BMT  was  developed 
empirically through animal and human experimentation 
before the identification and characterization of HSCs. 
The  extraordinary  history  of  BMT  and  its  clinical 
development have much to teach us now about how to 
turn  current  strategies  in  the  stem  cell  field  into  new 
therapies. For example, although first conceived to treat 
blood  disorders,  BMT  is  gaining  momentum  in  the 
treatment  of  non-hematological  and  non-malignant 
diseases [2].
Current  excitement  regarding  stem  cells  rests  on 
several  converging  themes.  The  derivation  of  ES  cells, 
first  of  mouse  and  then  of  human  origin,  provided  a 
platform for the study of pluripotency and the in vitro 
generation of different cell types. Recent advances in our 
understanding of the molecular mechanisms underlying 
lineage  determination  and  differentiation  have  fueled 
methods  for  the  interconversion  of  cells  of  different 
lineages. In the most dramatic version of such cellular 
gym  nastics, Shinya Yamanaka and colleagues [3] demon-
strated that a small cocktail of regulatory factors can turn 
virtually any somatic cell into a pluripotent, ES-like cell 
in  a  process  known  as  cellular  reprogramming.  These 
induced  pluripotent  stem  (iPS)  cells  have  become  the 
focus  of  brigades  of  investigators,  particularly  because 
they provide a system in which to generate pluripotent 
cells from an individual of a specific genetic constitution 
(disease state), giving birth to the notion of ‘disease in the 
dish’.
Improved high-throughput methods, mostly supported 
by enhanced protein and DNA sequencing platforms, are 
being used to characterize the cellular proteome, trans-
criptome, and epigenome (DNA methylation and histone 
modifications)  in  comprehensive  and  exhaustive  detail. 
The vast data from these approaches provide a framework 
in which to consider the molecular mechanisms under-
lying cell fate decisions. As cell choice is at the heart of 
stem cell biology, this knowledge base will guide future 
research  into  manipulating  normal  or  disease-related 
cells for ultimate therapeutic benefit.
This series of articles provides a sense of the breadth 
and scope of the contemporary stem cell scene. The field 
touches nearly every corner of medical science. What can 
we  reasonably  expect  in  the  coming  years?  Making 
predictions  is  a  risky  business;  nonetheless,  I  will  try. 
First, the exploitation of ‘disease in a dish’ should lead to 
critical new insights into disease processes and stimulate 
new therapeutic strategies. Second, we should anticipate 
the development of new therapies based on the stimu-
lation of endogenous stem cells for tissue repair or for 
reversing  the  effects  of  aging,  perhaps  well  before  the 
development of cells as regenerative medicine products. 
Third, the use of specific cell types produced from human  © 2010 BioMed Central Ltd





Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02116, USA
Orkin Genome Medicine 2011, 3:34 
http://genomemedicine.com/content/3/6/34
© 2011 BioMed Central Ltdpluripotent cells, especially of defined genotypes, should 
improve the screening of drug toxicity and reduce the 
overall costs of drug development. Fourth, the connec-
tions between epigenetic regulation in pluripotent cells 
and cancer cells will forge innovative approaches to epi-
genetic therapy of malignant conditions, and possibly the 
contribution of epigenetic modulation to non-malignant 
conditions. Fifth, ex vivo methods for the generation of 
specific  cell  types  from  pluripotent  cells  or  by  direct 
lineage interconversion should drive bioengineering and 
fuel the next advances in the creation of artificial organs. 
And finally, with an increased ability to manipulate and 
generate  stem  cells  of  various  tissues  will  come  the 
potential  to  use  gene  modification  to  correct  genetic 
defects or enhance cellular capacities. Such work should 
stimulate advances in somatic gene therapy of disease.
Although the applications of stem cell biology may be 
dazzling, it is critical to support fundamental work in the 
stem cell arena, as only that will ensure a solid foundation 
for  clinical  translation  and  lead  to  those  unexpected 
discoveries  that  drive  future  innovation.  We  hope  that 
this series on translational stem cell genomics provides a 
glimpse into this remarkable field.
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